We are live on !
Find out more
State Street SPDR S&P Biotech ETF
123 hedge funds and large institutions have $1.05B invested in State Street SPDR S&P Biotech ETF in 2013 Q2 according to their latest regulatory filings, with 123 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
38% less call options, than puts
Call options by funds: $28.1M | Put options by funds: $45.5M
Holders
123
Holders Change
+123
Holders Change %
–
% of All Funds
4%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.13%
New
123
Increased
–
Reduced
–
Closed
–
Calls
$28.1M
Puts
$45.5M
Net Calls
-$17.4M
Net Calls Change
-$17.4M
Top Buyers
No buyers this quarter
Top Sellers
No sellers this quarter
XBI Hedge Fund Activity: Q2 2013 in Review
123 of the 3,075 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2013, worth a combined $1.05B.
Buyers outnumbered sellers: 123 funds opened new XBI positions and 0 closed out — a net gain of 123 holders — while 0 added to existing stakes and 0 trimmed.
- 123 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $1.05B of State Street SPDR S&P Biotech ETF stock for Q2 2013.
- 123 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2013 and 0 closed out, a net change of +123 holders.
Based on aggregated 13F filings for Q2 2013.